Immune checkpoint blockade (ICB) has two main limitations: responses vary between subgroups of patients and immune-related adverse events (irAEs) can be severe. To assess the mechanism of action behind the induction and variability of such responses...Read More
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production
The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy
Last week, the ACIR team attended the CIMT Annual Meeting 2022 in Mainz, Germany. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Personalized cancer immunotherapyAlena Gros VidalHajer Fritah...
IL-12 is of great interest for immunotherapy for its broad immune-activating effects. However, systemic treatment induces severe toxicities, limiting its application. Approaches to safely deliver cytokines to the tumor microenvironment are therefore warranted. Jones and Nardozzi et al. investigated a...
Sex bias in the development, aggressiveness, and mortality of cancer is a well documented phenomenon that cannot be fully explained by behavioral, physical, or genetic differences. Looking into potential immunological mechanisms as to how biological sex, as defined by...
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:Donate to support researchers
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Katherine J. Turner
Samuel (Sandy) Goldman
Elaine Yee Lin Chung
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
In less than a minute, link your credit card with our partner RoundUp App.
Every purchase you make with that card will be rounded up and the change will be donated to ACIR.
All transactions are securely made through Stripe.